clinical trial · NCT00406640
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women
Wyeth is now a wholly owned subsidiary of Pfizer·phase3·completed·n = 595
DepressionDepressive DisorderDepressive Disorder, MajorDesvenlafaxine succinate sustained-release (DVS SR)Escitalopram
brief summary
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). This study will investigate the safety, efficacy, and tolerability of DVS SR versus escitalopram in women with major depressive disorder (MDD) who are postmenopausal.
started
Dec 1, 2006
primary completion
Feb 1, 2008
completion
Oct 1, 2008
last updated
Dec 28, 2023
official title
A Multicenter, Randomized, 8-Week Double-Blind Acute Phase Followed By a 6-Month Continuation Phase (Open-Label Or Double-Blind) Study to Evaluate the Efficacy, Safety, and Tolerability of DVS SR Versus Escitalopram in Postmenopausal Women With Major Depressive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol